DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Cancer

Treatments: Drug: Recentin (Cediranib)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00748891

EDRACT nbr 2007-006251-39

D1330C00003

Details and patient eligibility

About

This study is being carried out in patients with advanced solid tumours to assess which of two different types of imaging scans best measures activity of an experimental drug called Cediranib. The study compares the imaging tests: Dynamic Contrast Enhanced CT (DCE-CT) and Dynamic Contrast Enhanced MRI (DCE-MRI). It looks at which of these scans is the most accurate and best predicts a response to the treatment. Cediranib is thought to work by stopping blood flow to cancers, and both of these scans assess blood flow. Studying the response of cancers by measuring changes in their blood flow may provide useful information that will guide the way we manage cancers in the future.

Enrollment: 35 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed metastatic tumour which is refractory to standard therapies
• At least one lesion size ≥3cm on in longest diameter suitable for repeat assessment by DCE-CT and DCE-MRI
• Patients must be able to undergo DCE-CT and DCE-MRI scanning procedures
• Life expectancy of at least 12 weeks

Exclusion criteria

• Patients with hormone refractory prostate cancer (HRPC)
• Patients with a history of poorly controlled high blood pressure
• Ineligibility for MRI scanning or DCE-CT or DCE-MRI scanning

Trial design

35 participants in 1 patient group

1

Experimental group

Description:

Open label 30mg Cediranib administered once daily during scanning phase and if tolerated by patient, until disease progression

Treatment:

Drug: Recentin (Cediranib)